The HER2CLIMB-02 trial, results of which were presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-10), examined a combination of two HER2-targeted drugs in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
